This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Diabetes Mellitus  • Treatment Adherence  • Adherence  • Alert me on articles by topic

Mike Mitka

JAMA. 2007;298:614-615.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Chicago—The approval in 2006 of continuous glucose monitoring (CGM) devices brought hopes that providing patients with type 1 diabetes with real-time information from a sensor implanted just under the skin would allow them to achieve better glycemic control. However, researchers have had a tough time showing efficacy of CGM in the clinic due to such factors as problems with device calibration and a lack of rigorous trial data.

A study presented at the American Diabetes Association’s 67th Scientific Sessions, held here in June, suggests that yet another element may limit how well CGM translates into glycemic control: patients who are indifferent to taking action to adjust their blood glucose level based on the information generated by CGM.

A continuous glucose monitor makes frequent measurements that provide patients an opportunity for improved glycemic control. (Photo credit: Medtronic, Inc.)

In a 6-month randomized multicenter trial, 138 experienced insulin pump . . . [Full Text of this Article]